Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer
-
Published:2020-06
Issue:
Volume:479
Page:89-99
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Takeyama Yuji,
Kato Minoru,
Tamada SatoshiORCID,
Azuma Yukari,
Shimizu Yasuomi,
Iguchi Taro,
Yamasaki Takeshi,
Gi Min,
Wanibuchi Hideki,
Nakatani Tatsuya
Subject
Cancer Research,Oncology
Reference48 articles.
1. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J. Clin. Oncol.,2000
2. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder;Ortmann;Future Oncol.,2013
3. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma;Takeyama;Int. J. Clin. Oncol.,2018
4. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017
5. ≤jco.18.02257.pdf>.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献